190711-56-9

Basic information

• Product Name: Benzenesulfonyl chloride, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
• CAS NO: 190711-56-9
• Molecular Formula: C17H12ClF3N2O2S
• Molecular Weight: 400.809
• Mol File: 190711-56-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzenesulfonyl chloride, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonyl chloride, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-(190711-56-9)
• EPA Substance Registry System: Benzenesulfonyl chloride, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-(190711-56-9)

Safety Data

• Hazardous Substances Data: 190711-56-9(Hazardous Substances Data)

Upstream product

• 169590-42-5 4-[5-(4-(methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide 
• 720-94-5 4,4,4-trifluoro-1-(4-methylphenyl)butane-1,3-dione 
• 921617-76-7 4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonic acid 
• 190711-64-9 Acetic acid 4-(5-p-tolyl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonylmethyl ester 
• 190711-47-8 1-(4-Methanesulfinyl-phenyl)-5-p-tolyl-3-trifluoromethyl-1H-pyrazole 
• 365530-13-8 4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]aniline 
• 190711-63-8 Acetic acid 4-(5-p-tolyl-3-trifluoromethyl-pyrazol-1-yl)-phenylsulfanylmethyl ester 
• 122-00-9 para-methylacetophenone 

Downstream Products

• 169590-42-5 4-[5-(4-(methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide 
• 921617-79-0 (R,S)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-1-yl)-benzensulfonylamino-oxy]-propionic acid 

Relevant articles and documents

Neuroprotective effect of novel celecoxib derivatives against spinal cord injury via attenuation of COX-2, oxidative stress, apoptosis and inflammation

A novel series of celecoxib derivatives were synthesized and evaluated for cyclooxygenase (COX-1/COX-2) inhibitory activities for benefit in spinal cord injury (SCI). The title compounds were synthesized by conventional methods in good yields and subsequently tested for inhibitory activity against COX-1/COX-2. The most potent COX-2 inhibitor among the tested derivatives was further assayed for protective effect against experimental SCI of Sprague-Dawley rats. The designed compounds showed considerable inhibition of COX-2 as compared to COX-1 revealing compound 7m as most potent inhibitor of COX-2 isoenzyme (IC50 = 0.04 μM). The expression of mitochondrial apoptotic genes (Bcl-2 and Bax) together with COX-2 and iNOS was restored near to normal as evidenced by western blot analysis in SCI rats. Taken altogether, compound 7m was identified as most potent inhibitor of COX-2. It also showed protective action against SCI via attenuation of COX-2, oxidative stress and apoptosis and inflammation in Male Sprague-Dawley rats.

Preparation method of celecoxib genotoxic impurity

The invention provides a preparation method of a celecoxib genotoxic impurity. The method comprises the following steps: step 1, cyclizing G1 and G2 to generate G3; step 2, carrying out sulfonylationon the G3 to obtain G4; 3, generating G5 by the G4, name

New celecoxib derivatives as anti-inflammatory agents

A series of 1,5-diarylpyrazoles with a substituted benzenesulfonamide moiety was synthesized and evaluated for cyclooxygenase (COX-1/COX-2) inhibitory activities. Some compounds, for example, (±)-2-[4-(5-p-tolyl-3- trifluoromethyl-pyrazole-1-yl)-benzenesulfonylaminooxy]-propionic acid 16 and its disodium salt 21, had a higher in vivo anti-inflammatory activity compared to celecoxib, despite having no in vitro COX-1 or COX-2 inhibitory activity. Their gastrointestinal side effect profile is essentially more favorable than that of celecoxib.